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Silent myocardial ischemia as detected on Holter electro-
cardiographic (ECG) monitoring is present in >50% of
patients with unstable angina despite intensive medical
therapy. The presence and the extent of silent ischemia
have been correlated with an increased risk of early (1
month) unfavorable outcome including myocardial in-
farction and need for coronary revascularization for per-
sistent symptoms. Seventy patients with unstable angina
who had undergone continuous ECG monitoring for si-
lent ischemia were followed up for 2 years; 37 patients
(Group I) had Holter ECG evidence of silent ischemia
at bed rest in the coronary care unit during medical
treatment with nitrates, beta-receptor blockers and cal-
cium channel antagonists; the other 33 patients (Group
II) had no ischemic ST segment changes (symptomatic
or silent) on Holter monitoring.
Asymptomatic ischemic ST segment changes on continuous
Holter electrocardiographic (ECO) monitoring are common
in patients with coronary artery disease with stable (1-3)
and unstable (4-6) angina pectoris and are uncommon in
normal subjects (7). The presence of asymptomatic ST seg-
ment changes on Holter monitoring was previously dem-
onstrated (4) to identify patients at high risk for the early
(I month) development of myocardial infarction or need for
coronary revascularization for recurrent symptoms. We re-
cently completed a 2 year follow-up evaluation of a group
of 70 patients with unstable angina who underwent contin-
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Over a 2 year follow-up period, myocardial infarction
occurred in 10 patients in Group I (in 2 it was fatal)
compared with one nonfatal infarction in Group II (p
< 0.01 by Kaplan-Meier analysis); revascularization with
either coronary bypass surgery or angioplasty for symp-
tomatic ischemia was performed in 11 Group I and 5
Group II patients (p < 0.05). Multivariate Cox's hazard
analysis demonstrated that the presence of silent isch-
emia was the best predictor of 2 year outcome. There-
fore, persistent silent myocardial ischemia despite med-
ical therapy in patients with unstable angina carries
adverse prognostic implications that persist over a 2 year
period.
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uous Holter monitoring during the first 2 days in the coro-
nary care unit after hospital admission, while they were
being treated with combination medical therapy in a protocol
that included nitrates, beta-receptor blockers and calcium
channel antagonists. The goal of the present study was to
determine in these patients the long-term prognostic signif-
icance of silent ischemia detected on Holter monitoring with
respect to the 2 year clinical outcome of death and myo-
cardial infarction. The need for revascularization with either
bypass surgery or coronary angioplasty for recurrent symp-
toms was also assessed.
Methods
Study patients. The study group comprised 70 patients
with a clinical diagnosis of unstable angina who were treated
with combination triple drug medical therapy in two double-
blind, randomized, placebo-controlled trials (8,9). The el-
igibility criteria for the study were as follows: I) All patients
had unstable angina, defined as at least one episode of chest
pain at rest with documented ischemic (ECG) changes con-
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sisting of ST segment depression or elevation 2: I mm or T
wave inversion of pseudonormalization, 2) All patients were
hospitalized in the coronary care unit at The Johns Hopkins
Hospital or Francis Scott Key Medical Center, were placed
at bed rest and treated with long-acting nitrates, propranolol
(160 mg/day) and nifedipine (80 mg/day). There was no
upper age exclusion from the study. Patients with symp-
tomatic cerebrovascular disease, congenital heart disease,
symptomatic congestive heart failure, a prior history of car-
diac surgery or second degree or higher atrioventricular
(AV) block were excluded, as were patients with left bundle
branch block, left ventricular hypertrophy or other signifi-
cant severe rest abnormalities of the ST segment that would
interfere with the interpretation of the transient ST changes
on Holter monitoring. More than 95% of eligible patients
were approached for participation in the study, and of these
more than 80% agreed to participate and provided informed
consent. The decision for revascularization with bypass sur-
gery or coronary angioplasty was based on demonstrated
failure of medical therapy, consisting of at least two episodes
of recurrent rest angina with ischemic ECG changes, by
prior agreement of the full-time staff responsible for patient
care at both hospitals, All clinical decisions forthese patients
were made without knowledge of the results of Holter mon-
itoring. The study group was thus representative of patients
with rest angina who could be treated with combination
medical therapy in the coronary care unit setting.
Study design. Continuous ECG monitoring was per-
formed for a 48 hour period in the coronary care unit after
initiation of triple drug therapy, and the patients were fol-
lowed up for a 2 year period for I) the occurrence of death,
2) myocardial infarction defined by prolonged chest pain
with ECG changes and elevation of the creatine kinase level
to at least twice normal, and 3) the need for revascularization
with bypass surgery or coronary angioplasty for recurrent
symptoms, The results of continuous Holter monitoring were
not available to the physicians making the clinical decisions,
The Holter recordings were performed using the two leads
that had shown the most pronounced reversible ischemic
changes on the initial 12 lead ECG obtained during pain,
They were analyzed by two investigators who had no knowl-
edge of other data for the number and duration of ischemic
episodes defined by 2: I mm ST segment depression or el-
evation from baseline occurring 0,08 second after the J
point, lasting for at least I minute. Each episode was cor-
related with symptoms in the coronary care unit, and thereby
determined to be either symptomatic or silent. A normal
interval of at least 2 minutes was required after the resolution
of each episode before another discrete episode was counted.
The system utilized for Holter monitoring was an amplitude-
modulated reel to reel two channel monitor system.
Coronary angiography was performed in most (70%) but
not all patients, as clinically indicated, and the coronary
angiograms were analyzed without knowledge of other data
by two observers using visual estimations of the number of
major coronary arteries with 70 or 90% diameter stenoses.
Ergonovine provocation testing was not performed in the
presence of a stenosis of 2:70% diameter. Left ventricular
ejection fraction was determined by either contrast left ven-
triculography or radionuclide ventriculography using the gated
blood pool scan technique.
Data analysis. Continuous variables were analyzed us-
ing unpaired t tests of significance, and categorical data
were analyzed with chi-square tests as appropriate. Kaplan-
Meier analyses (10) were used to analyze the time-dependent
cumulative probability of clinical outcomes, using the meth-
ods of Breslow (11). A multivariate Cox's hazard function
analysis (12) was utilized to examine the predictive value
of 15 variables for 2 year clinical outcome; these included
age, sex, diabetes, hypertension, current cigarette smoking,
prior myocardial infarction, chest pain during the first 2
study days, silent ischemia detected by Holter monitoring,
ST segment elevation during the index episode of pain,
global ST changes during the index episode of pain, number
of coronary arteries with 2:70% or 2:90% diameter obstruc-
tion, left anterior descending coronary disease with 2':90%
diameter obstruction and left ventricular ejection fraction
obtained by contrast ventriculography or gated blood pool
scanning. Continuous independent variables such as age and
ejection fraction were included in the multivariate analysis
as continuous measures. The multivariate analysis examined
the relative risk afforded by each variable for the occurrence
Table 1. Two Year Adverse Clinical Outcomesfor Patients With and Without Silent ST
Segment Changes on Initial 48 Hour Holter Monitoring
Adverse Clinical Outcome
Cardiac death
Nonfatal MI
CABG or PTCA for symptoms
Total
Group I
Silent Ischemia
(n = 37)
~ }(27%)
II (30%)
21 (57%)
Group II
No Silent Ischemia
(n = 33)
n(3%)
5 (15%)
6 (18%)
p Value*
<0.01
<0.05
<0.00\
*Derived from Kaplan-Meier analysis. Breslow test. CABG = coronary bypass surgery; MI = myocardial
infarction; PTCA = percutaneous transluminal coronary angioplasty.
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I SILENT ISCHEMIAL. _ Figure 1. Kaplan-Meier curves illustrating the prob-
abilities of not experiencing death or myocardial in-
farction over the 2 year follow-up period for the 37
patients with (Group I) and the 33 patients without
(GroupII) silent ischemic ST changeson initial Holter
monitoring. The difference between the two groups is
significant at the p < 0.01 level.
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ysis) (Fig. I). When the 8 patients who had both sympto-
matic and silent ischemia in Group I are excluded, there
was a significantly higher risk of death or infarction over 2
years for the 29 Group I patients (p = 0.01) with only silent
Holter-detected ischemia than in the 33 Group II patients
without Holter-detected ST changes. Over the 2 year period,
II patients in Group I and 5 in Group II required coronary
bypass surgery or angioplasty for recurrent, medically re-
fractory symptoms (p < 0.05 by Kaplan-Meier analysis).
Thus, for the combined clinical outcomes of death, infarc-
tion or revascularization for recurrent symptoms as well,
1.0
0.2
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Figure 2. Relativerisk curvesderivedfromCox's hazardfunction
analysis demonstrating the risk for death, myocardial infarctionor
revascularization for recurrent symptoms and illustrating the ef-
fects of the silent ischemia (SI) and recurrent chest pain (CP)
variables on adverseoutcome. There is a fivefold relative risk for
outcomes associated with silent ischemia and a threefold relative
risk associated with chest pain during the initial 2 days. When
both variables are present, the relative risk for experiencing an
adverse outcome is increasedby a factor of 15.
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of the defined outcome. In a stepwise fashion it presented
the order in which the variables added information that
improved the ability to classify patients into predefined groups.
The relative risks of an unfavorable outcome over the 2 year
period were calculated. Data are presented as mean ± SO,
or as frequency, when appropriate.
The baseline clinical characteristics of the study group
have been previously described (4). The comparison groups
were as follows: 37 patients (Group I) had silent ischemic
ST changes on Holter monitoring and the other 33 (Group
II) had no ischemic ST changes on Holter monitoring. The
Group I patients had an average of 5.5 episodes each over
the 48 hour recording period; the median duration per ep-
isode was 20 minutes. Of the 37 patients in Group I, 8 had
symptoms associated with at least one episode, and episodes
of silent ST changes as well, whereas the other 29 patients
in this group had only silent episodes of ST changes on
Holter monitoring. During the first 2 days, nine Group II
patients had chest pain without accompanying ECG changes
on Holter monitoring. There were no significant baseline
differences between the two groups with regard to cardio-
vascular risk factors, medical therapy and extent of fixed
coronary artery disease at angiography; however, mean left
ventricular ejection fraction at rest was 56 ± 14% in Group
I patients versus 64 ± 13% for Group II (p < 0.05). Medical
therapy was continued over the 2 year period in the patients
who remained clinically stable and did not experience any
of the adverse study outcomes.
Two year clinical outcomes. The adverse clinical out-
comes over the 2 year follow-up period are presented in
Table I. Over the 2 year period, 10 patients in Group I
(27%) had a myocardial infarction that was fatal in 2. In
contrast, only one patient in Group II experienced a nonfatal
myocardial infarction over the 2 year period (p < 0.01 for
differences between the groups using Kaplan-Meier anal-
JACC Vol. 10, No.4
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there was a significantly greater incidence in Group I (21
of 37 patients, 57%) as compared with Group II (6 of 33
patients, 18%) (p < 0,001 by Kaplan-Meier analysis using
the Breslow test),
The Cox's hazardfunction analysis (Fig. 2) revealed that
silent Holter-detected ischemia was the most important pre-
dictor of an unfavorable outcome (death, infarction or need
for revascularization) over the 2 year follow-up period (p
< 0.001); the next most important variable was chest pain
during the initial 2 study days (p < 0.0 I). No other variable
was found to be a significant predictor of adverse 2 year
outcome in the presence of these two variables. The relative
risk curves for an unfavorable outcome was 5 in the presence
of silent ischemia and 3 for chest pain; it increased to 15
when both variables are present (Fig. 2).
Discussion
Patients with unstable angina pectoris have a high inci-
dence of silent myocardial ischemia as detected by contin-
uous Holter monitoring, even in the presence of combination
medical therapy that is sufficient in most cases to control
symptoms (4-6,13). Our previous report (4) demonstrated
that the presence and duration of silent ischemia are sig-
nificantly correlated with early (I month) unfavorable out-
come of infarction or recurrent symptoms requiring revas-
cularization. In the present report, 2 year follow-up of the
same study patients reveals that silent Holter-detected isch-
emia is significantly associated with an increased risk of
death or recurrent infarction over a 2 year period.
In the majority of patients, the adverse clinical outcome
occurred within the first several months. These observations
are consistent with the hypothesis that the development of
unstable angina is related to endothelial injury or disruption
due to a ruptured atherosclerotic plaque with superimposed
vasoconstriction or thrombus, or both, because the period
of highest risk during the first few months approximates the
time required for endothelial healing (14-16). Recent stud-
ies by Ludmer et al. (17) demonstrated an abnormal va-
soconstrictive response to acetylcholine (a potent vasodilator
in normal coronary arteries) in atherosclerotic coronary ar-
teries, suggesting that endothelial dysfunction may be a
mediator of inappropriate vasoconstriction. Other studies
(18,19) also identified muscarinic cholinergic defects in ex-
perimental and human atherosclerosis.
Clinical implications. This study suggests that the use
of Holter ECG monitoring for ST segment changes can be
used with other currently utilized data-including the initial
symptomatic response to therapy, the extent of myocardium
threatened by high grade coronary obstructions, left ven-
tricular function and results of low level exercise treadmill
testing-to provide additional risk stratification information
(20,21). It is difficult to directly compare the contributions
of ischemic ECG changes detected by Holter monitoring
and stress testing in this group, because many patients with
unstable angina experience an early adverse outcome before
stress testing can be performed. One advantage of Holter
monitoring is that it can be performed at any time in the
course of hospitalization. In addition, most of the episodes
of ischemic ST changes detected in these patients occur at
a low heart rate (9), suggesting that a primary reduction in
coronary blood flow rather than a response to increased
oxygen demands may play an important pathophysiologic
role in Holter-detected ischemia. Thus, Holter monitoring
and exercise stress testing may complement each other by
providing insight into both the amount of dynamic disease
activity (that is, vasoconstriction and platelet aggregation
and thrombosis) and the amount of fixed atherosclerotic
coronary disease as indicated by demand-related ischemia.
These findings suggest that the prognostic information
provided by Holter monitoring for ischemic ST changes
should be incorporated into clinical management of patients
with unstable angina. Cardiac catheterization and early coro-
nary revascularization (22,23) are clearly indicated for pa-
tients who do not respond to intensive medical therapy and
continue to experience chest pain after treatment with ni-
trates (24), beta-receptor blockers (9), calcium channel an-
tagonists (8), anticoagulants (25) and antiplatelet agents
(26,27). However, when symptoms of chest pain are con-
trolled with medical treatment it is difficult to identify which
patients may exhibit continued stability without further in-
terventional management. Use of the information obtained
from both Holter monitoring and low level exercise testing
(21) together with the anatomic information obtained from
cardiac catheterization may allow for a rational and tailored
management approach for both higher and lower risk patient
subgroups.
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